Physician profile
Erin E Legrand
NPI 1699009217
$1,463.50
in general payments reported to CMS, 2019-2025
14 companies · $21.00 in 2025
The $21.00 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $102 · 2021: $167 · 2022: $319 · 2023: $571 · 2024: $135 · 2025: $21.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.12 |
| Education | $107.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $400.62 | 2020-2023 | Acessa Provu System, Omni Hysteroscope |
| Abbvie INC. | $259.92 | 2019-2023 | |
| Astellas Pharma US INC | $168.72 | 2023-2024 | Veozah |
| Therapeuticsmd, INC. | $161.55 | 2019-2021 | |
| Conmed Corporation | $154.85 | 2023-2024 | |
| Coopersurgical, INC. | $110.70 | 2022-2023 | Paragard T 380a |
| Medtronic USA, INC. | $44.60 | 2019 | |
| Myovant Sciences INC. | $40.35 | 2021-2022 | |
| Biogen, INC. | $29.90 | 2024 | Zurzuvae |
| Kci USA, INC. | $21.43 | 2023 | V.A.C.Ulta, Prevena |
| Glaxosmithkline, LLC. | $21.00 | 2025 | Nucala |
| Sumitomo Pharma America, INC. | $19.79 | 2024 | Myfembree |
| Aspira Women'S Health INC | $15.04 | 2023 | Ova1 |
| Baxter Healthcare | $15.03 | 2023 | Tisseel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Legrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.